Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Complementary and Alternative Medicine

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Antimicrobial activity and cytotoxicity of the ethanol extract, fractions and eight compounds isolated from Eriosema robustum (Fabaceae)

  • Maurice D Awouafack1, 2,
  • Lyndy J McGaw1,
  • Sebastian Gottfried3,
  • Roukayatou Mbouangouere2,
  • Pierre Tane2,
  • Michael Spiteller3 and
  • Jacobus N Eloff1Email author
BMC Complementary and Alternative MedicineThe official journal of the International Society for Complementary Medicine Research (ISCMR)201313:289

https://doi.org/10.1186/1472-6882-13-289

Received: 27 April 2013

Accepted: 25 October 2013

Published: 29 October 2013

Abstract

Background

The aim of this study was to evaluate the antimicrobial activity and the cytotoxicity of the ethanol crude extract, fractions and isolated compounds from the twigs of Eriosema robustum, a plant used for the treatment of coughs and skin diseases.

Methods

Column chromatographic and spectroscopic techniques were used to isolate and identify eight compounds, robusflavones A (1) and B (2), orostachyscerebroside A (3), stigmasterol (4), 1-O-heptatriacontanoyl glycerol (5), eicosanoic acid (6), 3-O-β-D-glucopyranoside of sitosterol (7) and 6-prenylpinocembrin (8), from E. robustum. A two-fold serial microdilution method was used to determine the minimum inhibitory concentration (MIC) against fungi and bacteria, and the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide reduction assay was used to evaluate the cytotoxicity.

Results

Fraction B had significant antimicrobial activity against Aspergillus fumigatus and Cryptoccocus neoformans (MIC 0.08 mg/ml), whilst the crude extract and fraction A had moderate activity against A. fumigatus and Candida albicans (MIC 0.16 mg/ml). Fraction A however had excellent activity against Staphylococcus aureus (MIC 0.02 mg/ml), Enterococcus faecalis and Escherichia coli (MIC 0.04 mg/ml). The crude extract had significant activity against S. aureus, E. faecalis and E. coli. Fraction B had good activity against E. faecalis and E. coli (MIC 0.08 mg/ml). All the isolated compounds had a relatively weak antimicrobial activity. An MIC of 65 μg/ml was obtained with robusflavones A (1) and B (2) against C. albicans and A. fumigatus, orostachyscerebroside A (3) against A. fumigatus, and robusflavone B (2) against C. neoformans. Compound 8 had the best activity against bacteria (average MIC 55 μg/ml). The 3 fractions and isolated compounds had LC50 values between 13.20 to > 100 μg/ml against Vero cells yielding selectivity indices between 0.01 and 1.58.

Conclusion

The isolated compounds generally had a much lower activity than expected based on the activity of the fractions from which they were isolated. This may be the result of synergism between different compounds in the complex extracts or fractions. The results support the traditional use of E. robustum to treat infections. The crude extract had a good activity and low preparation cost, and may be useful in topical applications to combat microbial infections.

Keywords

Eriosema robustum FabaceaeFlavonoidsAntimicrobialCytotoxicity

Background

The need for new, effective and affordable drugs to treat microbial diseases in the developing world is one of the issues facing global health today. Available drugs for the treatment of these diseases are limited by factors ranging from microbe resistance to safety, compliance and cost. The use of medicinal plants for curative purposes is as old as mankind and can be traced from the beginning of civilisation. The interaction between man and his environment is such that his food, shelter, the diseases that afflict him and the cure of such diseases are all within the environment. Thus, man uses his environment and the resources of nature to combat diseases that afflict him. Consequently over many centuries, people of various countries of the world have embarked on what is now known as traditional medicine [1]. It is estimated that plants are still a major source of primary healthcare for more than 60% of the world’s population.

Eriosema robustum, a member of Fabaceae family, is a perennial non-climbing shrub with yellow flowers native to Burundi, Ethiopia, Kenya, Rwanda, Tanzania, Uganda, Democratic Republic of Congo and Cameroon [2]. It is used traditionally for the treatment of coughs in East Africa [3] and skin diseases in the Western Region of Cameroon. Previous phytochemical study on this species led to the isolation and characterization of two flavonoids, robusflavones A and B, and five known compounds [4]. As part of our ongoing study for bioactive secondary metabolites from species of the Fabaceae family [46], we have re-investigated the ethanol extract of the twigs of E. robustum using bioassay-guided fractionation. To investigate the potential use of an extract, fractions or compounds, the cellular toxicity also has to be determined. The therapeutic index, that is, ratio of activity against microorganisms to toxicity to animal cells, is important.

We report herein the antimicrobial activity and cytotoxicity of the crude extract, fractions and the isolated compounds (18). This is also the first report on the isolation of a cerebroside, orostachyscerebroside A (3), from the genus Eriosema.

Methods

Plant material

The twigs of E. robustum were collected in Dschang, Western Region of Cameroon, in December 2011 and identified at the Cameroon National Herbarium in Yaoundé where a specimen was deposited under a voucher number 35291/HNC.

Extraction and isolation

The dried and powdered twigs of E. robustum (2 kg) were extracted for three days in ethanol (10 litres × 3 times) to yield the crude extract (115 g) after filtration and solvent evaporation using a rotary evaporator. Part of this extract (5 g) was subjected to a silica gel column chromatography eluted with n-hexane (Hex), chloroform (CHCl3), ethyl acetate (EtOAc) and methanol (MeOH) in increasing polarity to give 40 fractions of 500 ml each that were combined after monitoring with comparative thin layer chromatography (Co-TLC) into 3 fractions: A [(0.9 g, Hex - CHCl3 (100:0, 4:1, 3:2, 1:4) and CHCl3 - EtOAc (100:0, 4:1)], B [(0.7 g, CHCl3 - EtOAc (4:1, 3:2, 1:4) and C [(2.5 g, CHCl3 – EtOAc (1:4) and EtOAc - MeOH (100:0, 3:7, 0:100)]. Fraction C did not have as many active antimicrobial constituents separated by TLC in bioautography as fractions A and B, and was not further investigated.

Fraction B was subjected to purification applying silica gel column chromatography eluted with n-hexane, acetone and methanol in order of increasing polarity to yield 50 fractions of 150 ml each which were combined in subfractions after monitoring with Co-TLC. Subfractions F25-26 and F27-30 eluted with n-hexane: acetone (17:3) gave compounds 2 (9 mg), 4 (8 mg) and 6 (12 mg). Subfractions F20-26 eluted with n-hexane: acetone (7:3, 3:2) and F27-35 eluted with n-hexane: acetone (11:9, 1:9) were similarly subjected to further silica gel column chromatography eluted with n-hexane, ethyl acetate, methanol in gradient polarity followed by preparative TLC and Sephadex LH-20 to yield 1 (4 mg), 3 (10 mg), 5 (7 mg) and 7 (9 mg).

Fraction A was subjected to Sephadex LH-20 to remove chlorophyll and the eluate was concentrated and fractionated using similar silica gel column techniques as described above for fraction B to give mainly 4 (3 mg) and 8 (17 mg).

Orostachyscerebroside A (3): colourless amorphous; 1H NMR (DMSO-d 6 , 400 MHz): δ 4.38 (br.t, 4.0 Hz, H-1b), 4.58 (br.t, 4.0 Hz, H-1a), 4.08 (m, H-2), 3.76 (m, H-3), 3.70 (m, H-4), 1.86-2.02 (2H, m, H-5), 5.63 (8H, m, H-6/H-7/H-10/H-11/H-6′/H-7′/H-9′/H-10′), 1.23-1.33 (8H, m, H-8/H-12/H-5′/H-11′), 1.40-1.65 (2H, m, H-9), 1.24-1.31 (20H, m, H-13 to H-22), 1.50 (4H, m, H-23/H-19′), 0.84 (6H, t, 4.0 Hz, H-24/H-20′), 3.80 (m, H-2′), 1.26 (m, H-3′a), 2.02 (m, H-3′b), 1.02 (2H, m, H-4′), 1.02-1.20 (2H, m, H-8′), 1.20-1.33 (14H, m, H-12′ to H-18′), 4.12 (d, 8.0 Hz, Glc-1″), 3.32 (m, H-2″), 4.96 (m, H-3″), 3.60 (m, H-4″), 3.03 (m, H-5″), 3.38 (m, H-6″a), 3.65 (m, H-6″b), 7.55 (d, 8.0 Hz, NH); 13C NMR (DMSO-d 6 , 100 MHz) δ: 69.4 (C-1), 50.3 (C-2), 70.9 (C-3), 71.3 (C-4), 34.8 (C-5), 129.8 (C-6), 130.1 (C-7), 27.4 (C-8/C-11′), 32.2 (C-9), 130.3 (C-10), 130.7 (C-11), 31.8 (C-12), 29.0-30.9 (C-13 to C-22), 22.6 (C-23/C-19′), 14.4 (Me-24/Me-20′), 174.2 (C-1′), 71.3 (C-2′), 34.8 (C-3′), 24.4 (C-4′/C-8′), 27.1 (C-5′), 130.1 (C-6′/C-10′), 129.8 (C-7′/C-9′), 29.0-30.9 (C-12′ to C-18′), 103.9 (C-1″), 73.9 (C-2″), 76.9 (C-3″), 70.4 (C-4″), 77.3 (C-5″), 61.4 (C-6″); MALDI-FT-MS m/z: 866.6720 ([M + H]+, C50H92O10N), MALDI-FT-MS2 (CID at 45 eV) (rel. int.) m/z: 704.6171 [(M + H)-162, C44H82NO5, 51]+, 686.6065 [(M + H)-162-H2O, C44H80NO4, 70]+, 500.3176 [(M + H)-366, C26H46NO8, 100]+.

General experimental procedures

IR spectra were recorded on a Bruker Alpha FT-IR spectrometer (Optik GmbH, Germany). UV spectra were recorded on Thermo Electron Helios spectrophotometer (UVB 120726, England).

1H- and 13C-NMR spectra were recorded with a Bruker spectrometer at 500 MHz and a Varian spectrometer at 400 MHz. Chemical shifts (δ) were quoted in parts per million (ppm) from the internal standard tetramethylsilane (TMS). Deuterated solvents as dimethyl sulfoxide (DMSO-d 6 , for compounds 1, 2, 3, 7 and 8), and chloroform (CDCl3, for compounds 4, 5 and 6) were used for the NMR experiments. Mass spectrometry was performed on a Thermo Scientific LTQ-Orbitrap instrument coupled to a MALDI (matrix-assisted laser desorption ionization) or liquid chromatography electrospray ionization source. Column chromatography was performed on MN silica gel 60 (0.063-0.2 mm/70–230) mesh. Preparative TLC was performed using high-purity grade silica gel powder (60 A, 2–25 μm) Sigma-Aldrich, Germany. Pre-coated plates of TLC silica gel 60 F254 (Merck, Germany) were used for monitoring fractions and spots were detected with UV light (254 and 365 nm) and then sprayed with 30% H2SO4 followed by heating up to 110°C.

Antimicrobial assay

The two-fold serial microdilution method described by Eloff (1998) was used to determine the minimum inhibitory concentration (MIC) values for the extract, fractions and isolated compounds against bacteria [7] and a modification of [7] by Masoko et al. (2005) was used for fungi [8]. The respective MIC of the samples was determined using two Gram-positive bacteria, Staphylococcus aureus (ATCC 29213) and Enterococcus faecalis (ATCC 29212), two Gram-negative bacteria, Pseudomonas aeruginosa (ATCC 27853) and Escherichia coli (ATCC 25922); and three clinical isolates of the pathogenic fungi Candida albicans, Cryptococcus neoformans and, Aspergillus niger along with Candida albicans (ATCC 10231). Some fungal strains used were cultured from clinical cases of fungal infectious diseases in animals (before treatment) in the Department of Veterinary Tropical Diseases, Faculty of Veterinary Science. C. albicans was isolated from a Gouldian finch, C. neoformans from a cheetah, while A. fumigatus was isolated from a chicken which suffered from a systemic mycosis.

In the antibacterial tests, 100 μl of the (10 mg/ml) crude extract and fractions or (1 mg/ml) compounds in duplicate dissolved in dimethyl sulfoxide (DMSO) were serially diluted two-fold with sterile distilled water in 96-well microtitre plates and 100 μl bacterial culture in Mueller Hinton broth (MHB) (Fluka, Germany) was added to each well. DMSO was used to dissolve the compounds because acetone used in the original method [7] did not dissolve all the compounds well. The densities of bacterial cultures were approximately 2.6 × 1012 cfu/ml, S. aureus; 1.5 × 1010 cfu/ml, E. faecalis; 5.2 × 1013 cfu/ml, P. aeruginosa and 3.0 × 1011 cfu/ml, E. coli, obtained by adding 99 ml of MHB to 1 ml of each microorganism from the freshly prepared overnight bacterial culture in Mueller Hinton broth [9]. Gentamicin and DMSO were used as positive and negative controls, respectively. The microtitre plates were sealed in plastic bags to avoid contamination in the laboratory and were incubated overnight at 37°C. Afterwards, 40 μl of 0.2 mg/ml of p-iodonitrotetrazolium violet (INT) (Sigma, Germany) was added to each well to indicate microbial growth. The microtitre plates were further incubated at 37°C for 2 h and the minimal inhibitory concentration (MIC) was determined as the lowest concentration inhibiting microbial growth, indicated by a decrease in the intensity of the red colour of the formazan [10].

For the antifungal assay, 100 μl of the crude extract, fractions and compounds dissolved in DMSO at the same concentrations, as described above for the bacteria, were two-fold serially diluted with distilled water in 96-well microtitre plates, and 100 μl of fungal culture in Potato Dextrose broth (Sigma, Germany) was added to each well [8]. Amphotericin B and DMSO were used as positive and negative controls, respectively. INT (40 μl) at 0.2 mg/ml in distilled water was added to each well as a growth indicator and the covered microplates were incubated at 35°C after sealing in a plastic bag. The MIC value was recorded after 16 and 24 h incubation for C. albicans and A. fumigatus, and after 24 and 36 h incubation for C. neoformans as the lowest concentration of the sample that inhibited fungal growth. The colourless salt of tetrazolium acts as an electron acceptor and is reduced to a red coloured formazan product by biologically active organisms [11, 12]. The solution in the well remains clear or shows a marked decrease in intensity of colour after incubation with INT at the concentration where fungal growth is inhibited. The experiment was performed in triplicate and the standard deviation was zero.

Cytotoxicity assay

The MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) reduction assay is one of the most frequently used methods for measuring cell proliferation and cytotoxicity. The intensity of colour (measured spectrophotometrically) of the MTT formazan produced by living, metabolically active cells is proportional to the number of live cells present. MTT is a yellow water-soluble tetrazolium dye that is reduced by live, but not dead, cells to a purple formazan product that is insoluble in aqueous solutions. The viable cell growth after incubation with extract, fractions and isolated compounds was determined using the tetrazolium-based colorimetric MTT assay described by Mosmann (1983) [13]. In short, monkey Vero cells of a subconfluent culture were harvested and centrifuged at 200 × g for 5 min, and resuspended in growth medium to 5 × 104 cells/ml. The growth medium used was Minimal Essential Medium (MEM, Sigma) supplemented with 0.1% gentamicin (Virbac) and 5% foetal calf serum (Sigma). A total of 200 μl of the cell suspension is pipetted into each well of columns 2 to 11 of a sterile 96-well microtitre plate. A 200 μl aliquot of growth medium was added to wells of columns 1 and 12 to minimize the “edge effect” and maintain humidity. The plates were incubated for 24 h at 37°C in a 5% CO2 incubator, until the cells were in the exponential phase of growth. The MEM was aspirated from the cells, and replaced with 200 μl of extract, fractions and compounds at differing concentrations (serial dilution prepared in growth medium). The cells were disturbed as little as possible during the aspiration of medium and addition of test samples. Each dilution was tested in quadruplicate. The microtitre plates were incubated at 37°C in a 5% CO2 incubator for 48 h with test compounds, fractions or extract. Untreated cells and positive control (doxorubicin, Pfizer Laboratories) were included. After incubation, cells were washed with 150 μl phosphate buffered saline (PBS) and fresh MEM (200 μl) was added to each well together with 30 μl MTT (Sigma, stock solution of 5 mg/ml in PBS). The plates were then incubated for a further 4 h at 37°C. After incubation with MTT the medium in each well was carefully removed, without disturbing the MTT crystals in the wells. The MTT formazan crystals were dissolved by adding 50 μl DMSO to each well and the plates gently shaken until the MTT solution was dissolved. The amount of MTT reduction was measured immediately by detecting absorbance in a microplate reader (Versamax, Molecular Devices) at a wavelength of 570 nm and a reference wavelength of 630 nm. The wells in column 1, containing medium and MTT but no cells, were used to blank the plate reader. The LC50 values were calculated as the concentration of test sample resulting in a 50% reduction of absorbance compared to untreated cells.

Results and discussion

Chemical composition and antimicrobial activity

The EtOH crude extract from the twigs of Eriosema robustum was subjected to repeated silica gel column chromatography followed by preparative TLC and Sephadex LH-20 to afford eight compounds including robusflavones A (1, yellow amorphous, m/z 362, C17H14O9) and B (2, yellow amorphous, m/z 332, C16H12O8) [4], orostachyscerebroside A (3) [14], stigmasterol (4, white powder, m/z 412, C29H48O) [15], 1-O-heptatriacontanoyl glycerol (5, white powder, m/z 484, C30H60O4) [16], eicosanoic acid (6, white powder, m/z 312, C20H40O2) [17], 3-O-β-D-glucopyranoside of sitosterol (7, white crystals, m/z C35H60O6) [18] and 6-prenylpinocembrin (8, yellow, m/z C20H20O4) [19] (Figure 1). The structures elucidation of the compounds were achieved by interpretation of their NMR, IR, UV and MS data, and by comparison with those reported in the literature. To the best of our knowledge this is the first report on the isolation of a cerebroside, orostachyscerebroside A (3), from the genus Eriosema. Orostachyscerebroside A (3) was found for the first time in the aerial parts of Orostachys japonicas in 2012 [14].
Figure 1

Chemical structures of compounds (1–8) isolated from E. robustum.

The antimicrobial activity and cytotoxicity of the crude extract, fractions from the column chromatography of the extract and isolated compounds (18) were determined and the results are presented in Tables 1, 2 and 3. Many authors consider the antimicrobial activity of extracts to be significant if the MIC value is 0.1 mg/ml or lower, moderate if 0.1 < MIC ≤ 0.625 mg/ml and weak if MIC > 0.625 mg/ml [20, 21]. When reporting the antimicrobial activity of the isolated compounds, it is significant if the MIC is 10 μg/ml or lower, moderate if 10 < MIC ≤ 100 μg/ml and low if MIC > 100 μg/ml [21, 22]. Based on these criteria, all the tested samples had significant to weak antifungal activities against the four fungi with MIC values between 80 and 1250 μg/ml (Table 1). Fraction B was significantly active against Aspergillus fumigatus and Cryptoccocus neoformans with an MIC of 0.08 mg/ml, while the crude extract and fraction A had moderate activity against Aspergillus fumigatus and Candida albicans (ATCC) with an MIC value of 0.16 mg/ml in all cases. Fraction B had the highest antifungal activity among the tested fractions and extract with an average MIC of 0.61 mg/ml followed by fraction A (average MIC of 0.65 mg/ml) and the crude extract (average MIC of 0.88 mg/ml).
Table 1

Minimum inhibitory concentration (MIC) of the extract, fractions and compounds (1–8) from E. robustum against fungi (C.a, C.A, A.f, C.n) and bacteria (S.a, P.a, E.f, E.c)

Samples

Fungi (MIC values)

Bacteria (MIC values)

C.a

C.A

A.f

C.na

Average

S.a

P.a

E.f

E.c

Average

16 h

24 h

16 h

24 h

16 h

24 h

24 h

36 h

      

Extract and Fractions (mg/ml)

              

Crude extract

1.25

1.25

1.25

1.25

0.16

0.63

0.63

0.63

0.88

0.08

0.31

0.08

0.08

0.14

Fraction A

0.63

0.63

0.16

0.32

0.32

0.63

1.25

1.25

0.65

0.02

0.31

0.04

0.04

0.10

Fraction B

1.25

1.25

0.32

0.63

0.08

0.63

0.08

0.63

0.61

0.16

0.31

0.08

0.08

0.16

Compounds (μg/ml)

              

Robusflavone A (1)

250

250

65

65

65

125

250

250

165

250

63

250

250

203.3

Robusflavone B (2)

125

125

65

65

65

125

65

65

88

125

63

63

125

94

Orostachyscerebroside A (3)

250

250

130

250

130

250

250

250

220

125

63

125

125

109.5

Stigmasterol (4)

125

125

125

125

65

65

125

125

110

125

63

250

250

172

1-O-Heptatriacontanoyl glycerol (5)

250

250

65

65

125

125

250

250

173

125

63

125

125

109.5

Eicosanoic acid (6)

250

250

125

125

125

125

> 250

> 250

188

63

63

125

125

94

3-O-β-D-Glucopyranoside of sitosterol (7)

125

125

125

125

65

125

65

125

110

125

63

63

125

94

6-Prenylpinocembrin (8)

125

125

65

65

125

250

> 250

> 250

157

31.3

63

63

63

55.1

Controls (μg/ml)

              

Amp B

30

30

10

30

65

125

> 250

> 250

99

-

-

-

-

-

Gen

-

-

-

-

-

-

-

-

-

< 3.91

< 3.91

< 3.91

< 3.91

< 3.91

DMSOb

na

na

na

na

na

na

na

na

 

na

na

na

na

 

C.a: Candida albicans (isolate), C.A: Candida albicans (ATCC), C.n: Cryptococcus neoformans, A.f: Aspergillus fumigatus, E.c: Escherichia coli, E.f: Enterococcus faecalis, S.a: Staphylococcus aureus, P.a: Pseudomonas aeruginosa, Amp B: Amphotericin B, Gen: Gentamicin, aWith this microorganism little reaction was observed after 16 h and values were measured after 24 and 36 h, bThe final concentration of DMSO used was less than 10%, na: not active.

The results are the means of three replicates for fungi and two replicates for bacteria and the standard deviation was zero.

Table 2

Total activity in ml/g of crude extract and fractions (A and B) from E. robustum calculated by dividing mass in g of extract or fractions with their MIC values[20]

Samples

Fungi

Bacteria

C.a

C.A

A.f

C.n

Average

S.a

P.a

E.f

E.c

Average

16 h

24 h

16 h

24 h

16 h

24 h

24 h

36 h

      

Extract and Fractions

              

Crude extract

4000

4000

4000

4000

31250

7937

7937

7937

8883

62500

16129

62500

62500

50907

Fraction A

1429

1429

5625

2813

2813

1429

720

720

2123

45000

2903

22500

22500

23226

Fraction B

560

560

2188

1111

8750

1111

8750

1111

3018

4375

2258

8750

8750

6033

Compounds

              

Robusflavone A (1)

4

4

13.4

13.4

13.4

8

4

4

8

4

16

4

4

7

Robusflavone B (2)

8

8

13.4

13.4

13.4

8

13.4

13.4

11

8

16

16

8

12

Orostachyscerebroside A (3)

4

4

7.7

4

7.7

4

4

4

4.5

8

16

8

8

9.1

Stigmasterol (4)

8

8

8

8

13.4

13.4

8

8

9

8

16

4

4

8

1-O-Heptatriacontanoyl glycerol (5)

4

4

13.4

13.4

8

8

4

4

7

8

16

8

8

10

Eicosanoic acid (6)

4

4

8

8

8

8

< 8

< 8

7

16

16

8

8

12

3-O-β-D-Glucopyranoside of sitosterol (7)

8

8

8

8

13.4

8

13.4

8

9

8

16

16

8

12

6-Prenylpinocembrin (8)

8

8

13.4

13.4

8

4

< 4

< 4

8

32

16

16

16

20

C.a: Candida albicans (isolate), C.A: Candida albicans (ATCC), C.n: Cryptococcus neoformans, A.f: Aspergillus fumigatus, E.c: Escherichia coli, E.f: Enterococcus faecalis, S.a: Staphylococcus aureus, P.a: Pseudomonas aeruginosa.

The inverse of MIC in ml/mg was calculated for compounds (1 8).

Table 3

Cytotoxicity of the crude extract, fractions and compounds from E. robustum and their selectivity index (SI)

Samples

Cytotoxicty (LC50, μg/ml)

Selectivity indexa

 

C.a

C.A

A.f

C.n

S.a

P.a

E.f

E.c

Extract and fractions

         

Crude extract

53.45 ± 2.21

0.04

0.04

0.21*

0.08

0.67

0.17

0.67

0.67

Fraction A

17.91 ± 1.71

0.03

0.09*

0.05*

0.01

0.90

0.06

0.45

0.45

Fraction B

93.76 ± 25.62

0.08

0.22*

0.66*

0.66*

0.59

0.30

1.17

1.17

Compounds

         

Robusflavone A (1)

13.20 ± 0.02

0.05

0.20

0.16*

0.05

0.05

0.21

0.05

0.05

Robusflavone B (2)

30.42 ± 3.26

0.24

0.47

0.36*

0.47

0.24

0.48

0.48

0.24

Orostachyscerebroside A (3)

> 100

0.4

0.53*

0.53*

0.4

0.8

1.59

0.8

0.8

Stigmasterol (4)

54.97 ± 11.05

0.44

0.44

0.85

0.44

0.44

0.87

0.22

0.22

1-O-Heptatriacontanoylglycerol (5)

91.52 ± 28.38

0.37

1.41

0.73

0.37

0.73

1.45

0.73

0.73

Eicosanoic acid (6)

NT

-

-

-

-

-

-

-

-

3-O-β-D-Glucopyranoside of sitosterol (7)

>100

0.80

0.80

1.17*

1.17*

0.80

1.58

1.58

0.80

6-Prenylpinocembrin (8)

21.87 ± 0.37

0.17

0.34

0.13*

0.09

0.70

0.35

0.35

0.35

Control

         

Dox

3.32 ± 1.31

        

C.a: Candida albicans (isolate), C.A: Candida albicans (ATCC), A.f: Apergillus fumigatus, C.n: Cryptoccocus neoformans, E.c: Escherichia coli, E.f: Enterococcus faecalis, S.a: Staphylococcus aureus, P.a: s Dox: Doxorubicin with LC50 in μM, NT: not tested, aSI = LC50 /MIC, *SI obtained from average MIC.

The most active isolated compounds had moderate antifungal activity with the MIC value of 65 μg/ml. These included robusflavones A (1) and B (2) against C. albicans (ATCC) and A. fumigatus, compounds 4 and 7 against C. albicans (ATCC), as well as compound 6 against A. fumigatus and C.neoformans, orostachyscerebroside A (3) against A. fumigatus, and robusflavone B (2) against C. neoformans. Compounds 5 and 7 had weak antifungal activity against C. neoformans (MIC > 250 μg/ml in both cases). The animal pathogenic isolate C. albicans was more resistant to the tested samples with MIC values between 0.63 to 1.25 mg/ml for the extract and fractions and ranging from 125 to 250 μg/ml for compounds, respectively. Nevertheless, robusflavone B (2) had the best antifungal activity (average MIC of 88 μg/ml), followed by compounds 3 and 6 (average MIC of 110 μg/ml), compound 7 (average MIC of 157 μg/ml) and robusflavone A (1) (average MIC of 165 μg/ml).

The antibacterial activity of the crude extract, fractions and isolated compounds were determined against four bacteria with MIC values ranging from 0.02 to 0.31 mg/ml and from 31.3 to 250 μg/ml, respectively (Table 1). The crude extract had good activity against S. aureus, E. faecalis and E. coli (MIC value of 0.08 mg/ml) and had moderate activity against P. aeruginosa (MIC value of 0.31 mg/ml). Fraction A had excellent activity against S. aureus (MIC of 0.02 mg/ml), E. faecalis and E. coli (MIC of 0.04 mg/ml) and reasonable activity against P. aeruginosa (MIC value of 0.31 mg/ml). The Gram-negative P. aeruginosa and the Gram-positive S. aureus were more resistant to fraction B with MIC values of 0.31 and 0.16 mg/ml, respectively. However, fraction B had significant activity against E. faecalis and E. coli with an MIC value of 0.08 mg/ml. Compound 8 had moderate activity against S. aureus (MIC value of 31.3 μg/ml) and had reasonable activity against other bacteria with an MIC value of 63 μg/ml. Other constituents had also reasonable antibacterial activity against P. aeruginosa with the MIC value of 63 μg/ml as well as robusflavone B (2) and compound 6 against E. faecalis (MIC of 63 μg/ml). Amongst all the isolated compounds, 6-prenylpinocembrin (8) had the highest antibacterial activity with an average MIC of 55.1 μg/ml and average total activity of 20 ml/mg followed by robusflavone B (2), and compounds 5 and 6 (average MIC of 94 μg/ml and average total activity of 12 ml/mg), as well as robusflavone A (1) with an average MIC of 203.3 μg/ml and average total activity of 7 ml/mg.

The crude extract and fractions were found to be more active than the isolated compounds against the bacteria and the fungi. The antibacterial activity of fraction A is noteworthy against the bacteria with an average MIC value of 100 μg/ml [20, 23] and an average total activity of 23 226 ml/g. Fraction B had good antifungal activity against A. fumigatus and C. neoformans with an MIC value of 80 μg/ml and total activity of 8 750 ml/g after 16 and 24 h of incubation. This implies that if 1 g of fraction B from the ethanol extract was diluted to 8.75 litres it would still inhibit the growth of A. fumigatus and C. neoformans. Compound 8, obtained from the most antibacterial-active part, fraction A, had the highest antibacterial activity amongst all the isolated compounds with an average MIC of 55.1 μg/ml and average total activity of 20 ml/mg. The antibacterial activity of compound 8 is in agreement with previous results reported on the antimicrobial activity of similar compounds bearing the prenyl group on their structures [6, 24]. Robusflavones A (1) and B (2) characterized earlier as two new antioxidant flavones [4] had moderate activities against fungi and bacteria with mean MIC values of 165, 88, 203.3 and 94 μg/ml, and average total activities of 8, 11, 7 and 12 ml/mg, respectively. The cerebroside and the glycerol derivative (compounds 3 and 5) had similar antibacterial activity (both with average MIC of 109.5 μg/ml) but had slightly different antifungal activity with average MIC values of 220 and 173 μg/ml, respectively.

From the results, it is evident that the isolated compounds did not have good activity against the tested microorganisms as observed for extract and fractions. This supports the conclusion of Lewis and Ausubel (2006) that plants contain many compounds with low antimicrobial activity and use other mechanisms to combat microbial growth [25]. In some of our previous work, it has been found that crude extracts and fractions have excellent potential activity in treating microbial infections and may even have as good or higher activity than commercially used antimicrobials in the field or clinical trials [26, 27]. This could be justified by the fact that, constituents in plant extract or fractions interacting in a synergistic manner may not be highly active when they are not part of a mixture with synergistic compounds. The antimicrobial activity of the crude extract, fractions and compounds (13, 5, 6 and 8) are reported here for the first time.

Cytotoxicity

The crude extract, fractions and isolated compounds from the twigs of E. robostum were evaluated for their cytotoxicity against monkey kidney Vero cells in vitro using the MTT (3-(4,5-dimethylythiazol-2-yl)-2,5-diphenyl-2H-tetrazolium hydrobromide) assay and the results are presented in Table 3. Apart from eicosanoic acid (6) that was not tested, compounds 3 and 7 had LC50 value greater than 100 μg/ml whilst the crude extract, fractions and others isolated compounds (1, 2, 4, 5 and 8) had cytotoxic activity against the Vero cells with LC50 values ranging from 13.20 to 91.52 μg/ml. Our samples, and especially the tested compounds, could be considered less toxic than the positive control doxorubicin (LC50 = 3.32 μM) and by taking into consideration the criterion of the American National Cancer Institute (NCI) regarding the cytotoxicity of pure compounds (LC50 < 4 μg/ml) [28]. However, the LC50 values of 13.20, 30.42 and 21.87 μg/ml for compounds 1, 2 and 8 with the same basic skeleton (flavonoid) were lower than those of others compounds and more cell lines should be tested in a comprehensive screen to confirm their probable safety in terms of cytotoxicity. The selectivity index (SI) values of the tested samples ranged from 0.01 to 1.58 and could be considered as poor when taking in consideration that the ratio for a good therapeutic index for a remedy or drug should be ≥ 10 [29]. This is the first report on the cytotoxicity of the extract, fractions as well as compounds 1, 2, 3, 5 and 8 from E. robustum against Vero cells.

Fraction B had good antifungal activity with a total activity of 3018 ml/g for the fraction. One should keep in mind that the 5 g of extract separated by column chromatography was obtained from 87 g of the original dried plant material. In comparing the activity of different plants the concept of total activity was developed [30]. This indicates the volume to which level the extract from 1 g of dried plant material can be diluted and still inhibit the growth of the microorganism. The total activity of 3018 ml/g for fraction B was derived from 87 g of the original dried plant material. The total activity per gram dried plant material for fungi was therefore c. 35 ml/g. The same argument shows that fraction A had a total antibacterial activity of 267 ml/g dried plant material. The crude extract and fractions had fungistatic effect in most of the cases such as the crude extract against A. fumigatus, fraction A against C. albicans and A. fumigatus, and fraction B against C. albicans, A. fumigatus and C. neoformans. It is noteworthy that the crude extract had a fungicidal activity against the two Candida and the Cryptococcus species, but the fractions had mainly fungistatic activity. This again points to the probability of synergistic activities.

With the high total activity of the crude extract and the ease of preparation, there is a reasonable possibility that the crude extract can be used as topical treatment for fungal and especially bacterial infections. Manipulation of the extract by for example solvent-solvent fractionation may lead to extracts with a higher activity and possibly a lower cytotoxicity [31].

Conclusion

The results obtained support the traditional use of E. robustum to treat infections. The crude extract had good activity with low toxicity to animal cells, and may be useful in topical applications to combat microbial infections.

Declarations

Acknowledgements

The authors are grateful to the University of Pretoria for the Post-doctoral Fellowship awarded to MD Awouafack to work at the Faculty of Veterinary Science, Department of Paraclinical Sciences, Phytomedicine Programme, and the National Research Foundation and Medical Research Council for research funding.

Authors’ Affiliations

(1)
Phytomedicine Programme, Department of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria
(2)
Laboratory of Natural Products Chemistry, Department of Chemistry, Faculty of Science, University of Dschang
(3)
Institut für Umweltforschung (INFU) der Fakultät Chemie, Lehrstuhl für Umweltchemie und Analytische Chemie, Technische Universität Dortmund

References

  1. Ogungbamila O: Investigation of anti-infective activities of local plant materials used as drugs. Results, lessons learned, and prospects for development of sustainable research environments in developing countries. Edited by: Niemeyer HM. 1997, Santiago: IPICSGoogle Scholar
  2. Gillett JB, Polhill RM, Verdcourt B: Papilionoideae. Flora of Tropical East Africa, Leguminosae. Edited by: Milne-Redhead E, Polhill RM. 1971, London: Crown Agents for Overseas Governments and Administrations, 635-637. Part 4Google Scholar
  3. Kokwaro JO: Medicinal plants of East Africa. 2009, Nairobi: University of Nairobi Press, 335-3Google Scholar
  4. Awouafack MD, Tane P, Eloff JN: Two new antioxidant flavones from the twigs of Eriosema robustum (Fabaceae). Phytochemistry Lett. 2013, 6: 62-66. 10.1016/j.phytol.2012.10.017.View ArticleGoogle Scholar
  5. Awouafack MD, Spiteller P, Lamshöft M, Kusari S, Ivanova B, Tane P, Spiteller M: Antimicrobial isopropenyl-dihydrofuranoisoflavones from Crotalaria lachnophora. J Nat Prod. 2011, 74: 272-278. 10.1021/np1005218.View ArticlePubMedGoogle Scholar
  6. Awouafack MD, Kouam SF, Hussain H, Ngamga D, Tane P, Schulz B, Green IR, Krohn K: Antimicrobial prenylated dihydrochalcones from Eriosema glomerata. Planta Med. 2008, 74: 50-54. 10.1055/s-2007-993782.View ArticlePubMedGoogle Scholar
  7. Eloff JN: A sensitive and quick microplate method to determine the minimal inhibitory concentration of plant extracts for bacteria. Planta Med. 1998, 64: 711-713. 10.1055/s-2006-957563.View ArticlePubMedGoogle Scholar
  8. Masoko P, Picard J, Eloff JN: Antifungal activities of six South African Terminalia species (Combretaceae). J Ethnopharmacol. 2005, 99: 301-308. 10.1016/j.jep.2005.01.061.View ArticlePubMedGoogle Scholar
  9. Suleiman MM, McGaw LJ, Naidoo V, Eloff JN: Evaluation of several tree species for activity against the animal fungal pathogen Aspergillus fumigatus. S Afr J Bot. 2010, 76: 64-71. 10.1016/j.sajb.2009.07.001.View ArticleGoogle Scholar
  10. Shai LJ, McGaw LJ, Masoko P, Eloff JN: Antifungal and antibacterial activity of seven traditionally used South African plant species active against Candida albicans. S Afr J Bot. 2008, 74: 677-684. 10.1016/j.sajb.2008.04.003.View ArticleGoogle Scholar
  11. Mahlo SM, McGaw LJ, Eloff JN: Antifungal activity of leaf extracts from South African trees against plant pathogens. Crop Prot. 2010, 29: 1529-1533. 10.1016/j.cropro.2010.08.015.View ArticleGoogle Scholar
  12. Eloff JN: Which extractant should be used for the screening and isolation of antimicrobial components from plants?. J Ethnopharmacol. 1998, 60: 1-8. 10.1016/S0378-8741(97)00123-2.View ArticlePubMedGoogle Scholar
  13. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4.View ArticlePubMedGoogle Scholar
  14. Zhang H, Oh J, Jang T, Min BS, Na M: Glycolipids from the aerial parts of Orostachys japonicus with fatty acid synthase inhibitory and cytotoxic activities. Food Chem. 2012, 131: 1097-1103. 10.1016/j.foodchem.2011.09.058.View ArticleGoogle Scholar
  15. Forgo P, Kövér KE: Gradient enhanced selective experiments in the 1H NMR chemical shift assignment of the skeleton and side-chain resonances of stigmasterol, a phytosterol derivative. Steroids. 2004, 69: 43-50. 10.1016/j.steroids.2003.09.012.View ArticlePubMedGoogle Scholar
  16. Qi S-H, Zhang S, Huang J-S, Xiao Z-H, Wu J, Long L-J: Glycerol derivatives and sterols from Sargassum parvivesiculosum. Chem Pharm Bull. 2004, 52: 986-988. 10.1248/cpb.52.986.View ArticlePubMedGoogle Scholar
  17. Jain R, Sharma P, Bhagchandani T, Jain SC: Phytochemical investigation and antimicrobial activity of Acacia senegal root heartwood. J Pharm Res. 2012, 5: 4934-4938.Google Scholar
  18. Al-Oqail M, Hassan WHB, Ahmad MS, Al-Rehaily AJ: Phytochemical and biological studies of Solanum schimperianum Hochst. Saudi Pharm J. 2012, 20: 371-379. 10.1016/j.jsps.2012.05.010.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Caffaratti M, Ortega MG, Scarafia ME, Ariza Espinar L, Juliani HR: Prenylated flavanones from Dalea elegans. Phytochemistry. 1994, 36: 1082-1084. 10.1016/S0031-9422(00)90498-9.View ArticleGoogle Scholar
  20. Eloff JN: Quantification the bioactivity of plant extracts during screening and bioassay guided fractionation. Phytomedicine. 2004, 11: 370-371. 10.1078/0944711041495218.View ArticlePubMedGoogle Scholar
  21. Kuete V: Potential of Cameroonian plants and derived products against microbial infections: a review. Planta Med. 2010, 76: 1479-1491. 10.1055/s-0030-1250027.View ArticlePubMedGoogle Scholar
  22. Ríos JL, Recio MC: Medicinal plants and antimicrobial activity. J Ethnopharmacol. 2005, 100: 80-84. 10.1016/j.jep.2005.04.025.View ArticlePubMedGoogle Scholar
  23. Kuete V, Ango PY, Fotso GW, Kapche GDWF, Dzoyem JP, Wouking AG, Ngadjui BT, Abegaz BM: Antimicrobial activities of the methanol extract and compounds from Artocarpus communis (Moraceae). BMC Complement Altern Med. 2011, 11: 42-10.1186/1472-6882-11-42.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Awouafack MD, Kusari S, Lamshöft M, Ngamga D, Tane P, Spiteller M: Semi-synthesis of dihydrochalcone derivatives and their in Vitro antimicrobial activities. Planta Med. 2010, 76: 640-643. 10.1055/s-0029-1240619.View ArticlePubMedGoogle Scholar
  25. Lewis K, Ausubel FM: Prospects for plant derived antibacterials. Nat Biotechnol. 2006, 24: 1504-1507. 10.1038/nbt1206-1504.View ArticlePubMedGoogle Scholar
  26. Eloff JN, Angeh I, McGaw LJ: A potentised leaf extract of Melianthus comosus has higher activity than six commercial products used against plant fungal pathogens. S Afr J Bot. 2007, 73: 286-287.View ArticleGoogle Scholar
  27. Eloff JN, Suleiman M, Naidoo V: A crude extract of Loxostylus alata is as effective in treating aspergillosis in poultry as a commercial drug. Planta Med. 2010, 76: 405-View ArticleGoogle Scholar
  28. Tanamatayarat P, Limtrakul P, Chunsakaow S, Duangrat C: Screening of some Rubiaceous plants for cytotoxic activity against Cervix Carcinoma (KB-3-1) Cell Line. Thai J Pharm Sci. 2003, 27: 167-172.Google Scholar
  29. Caamal-Fuentes E, Torres-Tapia LW, Simá-Polanco P, Peraza-Sánchez SR, Moo-Puc R: Screening of plants used in Mayan traditional medicine to treat cancer-like symptoms. J Ethnopharmacol. 2011, 135: 719-724. 10.1016/j.jep.2011.04.004.View ArticlePubMedGoogle Scholar
  30. Eloff JN: A proposal on expressing the antibacterial activity of plant extracts - a small first step in applying scientific knowledge to rural primary health care in South Africa. S Afr J Sci. 2000, 96: 116-118.Google Scholar
  31. Eloff JN, Famakin JO, Katerere DRP: Combretum woodii (Combretaceae) leaf extracts have high activity against Gram-negative and Gram-positive bacteria. Afr J Biotechnol. 2005, 4: 1161-1166.Google Scholar
  32. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/289/prepub

Copyright

© Awouafack et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement